Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19770134 | 0.84 | KMT2A (0.36) | ABCB11CHRM2ADORA3AROPRM1 | |
| SCHEMBL25091834 | 0.72 | TLR9 (0.42) | — | |
| SCHEMBL25456677 | 0.68 | MAOA (0.50) | — | |
| SCHEMBL14925540 | 0.67 | TLR9 (0.41) | — | |
| SCHEMBL16624079 | 0.67 | PNMT (0.42) | ABCB11CHRM2ADORA3AROPRM1 | |
| SCHEMBL12090941 | 0.67 | ALDH1A1 (0.45) | — | |
| SCHEMBL2737322 | 0.67 | ALDH1A1 (0.49) | — | |
| SCHEMBL21411325 | 0.66 | KCNQ3 (0.39) | ABCB11CHRM2ADORA3AROPRM1 | |
| SCHEMBL10858296 | 0.66 | KMT2A (0.42) | ABCB11CHRM2ADORA3AROPRM1 | |
| SCHEMBL16624107 | 0.66 | GRIN2B (0.36) | ABCB11CHRM2ADORA3AROPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230030115-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO LTD (CN) | 2023-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230030115-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | ROCK1, ROCK2, RHOA | ABCB11 1662/4885CHRM2 2571/4885ADORA3 4037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.